Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Halozyme Therapeutics, a biopharmaceutical company developing and commercializing products targeting the extracellular matrix for the endocrinology, oncology, dermatology and drug delivery markets, has reported total revenue of $3.57m for the fourth quarter ended 31 December 2010, compared to $6.44m for the same period in 2009.
Subscribe to our email newsletter
Halozyme has posted net loss of $16.89m, compared to a net loss of $12.66m, for the same period in 2009.
The company’s operating loss was $17.88m for the fourth quarter ended 31 December 2010, compared to $12.68m for the same period in 2009.
For the full year of 2010, the company posted total revenue of $13.62m, compared to $13.67m for the same period in 2009.
Halozyme’s net loss was $53.24m for the full year of 2010, compared to a net loss of $58.36m for the same period in 2009.
The company has reported operating loss of $54.26m for the full year of 2010, as compare to $58.46m for the same period prior year.
Halozyme president and CEO Gregory Frost said their alliance partners should also demonstrate substantial progress in 2011 for products that utilize our technology as Baxter has stated it expects to file a BLA for HyQ (immunoglobulin subcutaneous) and Roche has stated it plans to announce top line data from the pivotal Phase 3 trial for subcutaneous Herceptin.